NMPA New Cosmetic Ingredient Regulation: What Global Buyers Must Know About the July 2026 Changes

Why This Regulation Matters Now

On June 26, 2026, the National Medical Products Administration (NMPA) published Announcement No. 59 — the *Provisions for Management of New Cosmetic Ingredient Registration and Notification Dossiers* — effective July 15, 2026. This replaces the 2021 framework and represents the most significant regulatory shift for cosmetic ingredient supply chains in years.

For global buyers, formulators, and procurement teams, this isn't just a compliance update. It's a supply chain restructuring event that changes time-to-market, costs, and competitive dynamics across the entire cosmetic ingredients sector.

The Three Core Changes

1. High-Risk Category Reduction: 10 → 5

The headline change: the "higher-risk functional claims" category has been reduced from 10 to 5 categories.

Still requiring Registration (highest scrutiny):

Now downgraded to Notification (simplified pathway):

What this means for your supply chain: Ingredients previously requiring 12–24 months of registration review can now enter the market through notification in as little as 3–6 months. For procurement teams, this translates to faster access to innovation ingredients and more supplier options.

2. Animal Alternative Testing Methods Accepted

The new regulation explicitly encourages animal alternative testing — including in vitro methods, computational toxicology, and AI-based safety assessment. This is critical for:

Alvokor BioSolution's compliance posture: Our safety assessment dossiers for cosmetic-grade ingredients are compiled using internationally accepted alternative testing frameworks, ensuring compatibility with CosIng registration, FDA food additive reviews, and REACH exempt bio-intermediate classifications where applicable.

3. Administrative-Technical Separation

The previous regulation embedded detailed technical requirements directly into the legal text. The new framework separates administrative provisions from technical guidelines, with the latter published as standalone documents by NIFDC (National Institutes for Food and Drug Control).

For overseas buyers, this means greater predictability in regulatory timelines and more transparent compliance requirements when sourcing from suppliers who maintain current notification dossiers.

What This Means for Overseas Buyers

If You Are Sourcing Anti-Acne or Anti-Wrinkle Actives

This is the highest-impact change. Ingredients like ectoine, nicotinamide, GHK-Cu, and novel HA derivatives used in anti-acne and anti-wrinkle formulations now follow the simplified notification pathway.

Action: Prioritize suppliers who already have pre-assembled notification packages for these ingredient categories.

If You Are Building Clean Beauty Supply Chains

The acceptance of alternative testing methods is a watershed moment for clean beauty regulation compliance. Ingredients sourced from suppliers with alternative testing data can now enter the market without the ethical and regulatory conflicts that animal testing creates.

If You Need Multi-Market Compliance

The convergence between NMPA's new framework and international standards (EU CosIng, FDA, REACH) means that a single well-structured dossier can now serve multiple regulatory jurisdictions more efficiently than before.

How Alvokor BioSolution Helps Clients Navigate the New Landscape

Pre-Assembled Notification Packages

For our core cosmetic active ingredients — Ectoine, Nicotinamide, Sodium Hyaluronate, GHK-Cu, Ceramides — Alvokor BioSolution maintains pre-assembled notification/registration documentation packages that align with both the new NMPA Technical Guidelines and international regulatory frameworks.

GMP-Certified Manufacturing

All cosmetic and pharma grade ingredients are produced in GMP-certified facilities, ensuring consistent batch-to-batch quality, full traceability, and documentation that meets the most stringent regulatory audit requirements.

Dosage-Form Innovation for Regulatory Differentiation

With 9 patents in advanced delivery systems, Alvokor BioSolution doesn't just supply commodity-grade ingredients. Our encapsulation and co-crystallization technologies create differentiated ingredient forms that can qualify for independent notification.

Timeline: What to Do Before and After July 15

FAQ

Q1: Does the new regulation lower safety standards?

A: No. The 3-year post-market safety monitoring period remains mandatory for all new ingredients. The regulation streamlines *administrative* and *procedural* requirements — it does not reduce safety assessment rigor.

Q2: My ingredient was already registered under the 2021 rules. Do I need to re-register?

A: No. Existing registrations and notifications remain valid. The new provisions apply to applications filed after July 15, 2026.

Q3: How does the alternative testing acceptance affect EU market access?

A: Positively. The alignment between NMPA's acceptance of alternative methods and the EU's long-standing animal testing ban means a single safety data package can now serve both markets more efficiently.

Q4: What is a "pre-assembled notification package"?

A: It's a complete set of documentation — safety assessment, stability data, impurity profile, manufacturing process description, and quality specifications — compiled in the format required by the NMPA Technical Guidelines.

Q5: How quickly can I get anti-acne ingredients to market under the new rules?

A: Under the notification pathway, typical timelines are 3–6 months from dossier submission to market access, compared to 12–24 months under the previous registration pathway.

Ready to navigate the new regulatory landscape? Whether you need a single ingredient with full compliance documentation or a multi-product sourcing strategy, Alvokor BioSolution provides the regulatory expertise, GMP manufacturing, and dosage-form innovation to accelerate your market entry.

📩 Contact us for free samples & full registration dossier at info@alvokorbio.com

🌐 Visit alvokorbiosolution.com for our complete product portfolio